Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex dose-finding for reversal of residual rocuronium neuromuscular block
2011-001683-22Phase 4Completed
- Sponsor
- University of Debrecen
- Start
- Apr 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in neuromuscular block (NMB) comparing Sugammadex arm with Neostigmine control arm (2 arms). Primary endpoint: Complete reversal of neuromuscular blockade. Started Apr 2011; status: completed.
02
Drugs
Sugammadexneostigmine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2011-001683-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001683-22.